Indicated for: prevention and treatment of thromboembolism
Route of administration: injectable
Substance: nadroparin (anticoagulant)
ATC: B01AB06 (Blood and blood forming organs | Antithrombotic agents | Heparin group)
Dose adjustment may be needed in kidney disease.
This medicine may have important interactions with other medicines.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
This medicine may increase the risk of bleeding.
Nadroparin is a low molecular weight heparin anticoagulant used for the prevention and treatment of deep vein thrombosis and pulmonary embolism. It works by inhibiting factor Xa, preventing the formation of blood clots.
The medication is administered via subcutaneous injection, usually once or twice daily, with the dose adjusted based on the patient's weight and therapeutic indication. Common side effects include bleeding, bruising at the injection site, and thrombocytopenia.
Nadroparin is contraindicated in patients with active bleeding, heparin-induced thrombocytopenia, or hypersensitivity to the active substance. Its use also requires careful monitoring to prevent hemorrhagic complications.
This medication is an effective option for the prevention and treatment of thromboembolic complications, helping to reduce the risk of severe cardiovascular events.